Compounds > vu0155069
Page last updated: 2024-08-03 12:13:52

vu0155069

Description

Cross-References

ID SourceID
PubMed CID25105713
CHEMBL ID492572
SCHEMBL ID4540618
MeSH IDM0589982

Synonyms (24)

Synonym
(s)-n-(1-(4-(5-chloro-2-oxo-2,3-dihydro-1h-benzo[d]imidazol-1-yl)piperidin-1-yl)propan-2-yl)-2-naphthamide
(s)-n-(1-(4-(5-chloro-2-oxo-2,3-dihydro-1h-benzo[d]imidazol-1-yl)piperidin-1-yl)propan-2-yl)naphthalene-2-carboxamide
(s)-n-(1-(4-(5-chloro-2-oxo-2,3-dihydro-1h-benzo[d]imidazol-1-yl)piperidin-1-yl)propan-2-yl)-2-naphthamide, 69
bdbm50258182
CHEMBL492572 ,
1130067-06-9
vu0155069
n-[(2s)-1-[4-(5-chloro-2-oxo-3h-benzimidazol-1-yl)piperidin-1-yl]propan-2-yl]naphthalene-2-carboxamide
gtpl8782
compound 69 [pmid: 19136975]
SCHEMBL4540618
cay10593
NCGC00370881-01
c26h27cln4o2
AKOS032961459
HY-108612
vu-0155069
E74843
Q27076766
mfcd23160355
n-[(1s)-2-[4-(5-chloro-2,3-dihydro-2-oxo-1h-benzimidazol-1-yl)-1-piperidinyl]-1-methylethyl]-2-naphthalenecarboxamide
CS-0029316
A936975
AC-36223

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency7.5637AID1645841
GVesicular stomatitis virusPotency0.2392AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency10.6840AID1645840
Interferon betaHomo sapiens (human)Potency0.2392AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency0.2392AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency0.2392AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency0.2392AID1645842

Inhibition Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Phospholipase D2Homo sapiens (human)IC501.3665AID418767; AID498478; AID498482; AID515549
Phospholipase D1 Rattus norvegicus (Norway rat)IC500.3310AID498481
Phospholipase D1Homo sapiens (human)IC500.2034AID1799395; AID1799396; AID1799399; AID418766; AID498477; AID498484; AID515548

Activation Measurements

ProteinTaxonomyMeasurementAverage (mM)Bioassay(s)
Phospholipase D1Homo sapiens (human)EC500.9055AID1799397; AID1799398

Bioassays (39)

Assay IDTitleYearJournalArticle
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
ISSN: 2472-5560		Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490		Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111		A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111		A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID498484Inhibition of human PLD1 assessed as release of methyl-[3H]choline from choline-methyl-[3H]dipalmitoylphosphatidylcholine after 30 mins by exogenous substrate assay2009Nature chemical biology, Feb, Volume: 5, Issue:2
ISSN: 1552-4469		Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID498481Inhibition of N-terminally truncated rat PLD1 assessed as release of methyl-[3H]choline from choline-methyl-[3H]dipalmitoylphosphatidylcholine after 30 mins by exogenous substrate assay2009Nature chemical biology, Feb, Volume: 5, Issue:2
ISSN: 1552-4469		Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID515548Inhibition of PLD1 in human calu1 cells2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
ISSN: 1520-4804		Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitor.
AID498470Inhibition of PLD1 mediated cancer cell migration in mouse 4T1 cells at 0.2 uM by transwell invasion assay2009Nature chemical biology, Feb, Volume: 5, Issue:2
ISSN: 1552-4469		Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID498472Inhibition of PLD2 mediated cancer cell migration in mouse 4T1 cells at 20 uM by transwell invasion assay2009Nature chemical biology, Feb, Volume: 5, Issue:2
ISSN: 1552-4469		Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID498478Inhibition of GFP-tagged human PLD2 expressed in human HEK293 cells assessed as decrease in phosphatidylbutanol-[d9] production after 30 mins by mass spectrometric analysis2009Nature chemical biology, Feb, Volume: 5, Issue:2
ISSN: 1552-4469		Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID515549Inhibition of human GST-tagged PLD2A in human HEK293 cells2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
ISSN: 1520-4804		Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitor.
AID498292Inhibition of PLD2 mediated cancer cell migration in mouse 4T1 cells at 0.2 uM by transwell invasion assay2009Nature chemical biology, Feb, Volume: 5, Issue:2
ISSN: 1552-4469		Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID498476Inhibition of PLD1 mediated cancer cell migration in human MDA-231 cells at 20 uM by transwell invasion assay2009Nature chemical biology, Feb, Volume: 5, Issue:2
ISSN: 1552-4469		Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID418766Inhibition of human PLD1 in Calu1 cells2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
ISSN: 1464-3405		Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity.
AID498291Inhibition of PLD1 mediated cancer cell migration in human MDA-231 cells at 200 nM by transwell invasion assay2009Nature chemical biology, Feb, Volume: 5, Issue:2
ISSN: 1552-4469		Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID498469Inhibition of PLD1 mediated cancer cell migration in human MDA-231 cells at 0.2 uM by transwell invasion assay2009Nature chemical biology, Feb, Volume: 5, Issue:2
ISSN: 1552-4469		Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID498288Inhibition of PLD1 mediated cancer cell migration in mouse PMT cells at 200 nM by transwell invasion assay2009Nature chemical biology, Feb, Volume: 5, Issue:2
ISSN: 1552-4469		Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID498289Inhibition of PLD1 mediated cancer cell migration in mouse 4T1 cells at 200 nM by transwell invasion assay2009Nature chemical biology, Feb, Volume: 5, Issue:2
ISSN: 1552-4469		Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID498290Inhibition of PLD2 mediated cancer cell migration in mouse PMT cells at 0.2 uM by transwell invasion assay2009Nature chemical biology, Feb, Volume: 5, Issue:2
ISSN: 1552-4469		Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID498473Inhibition of PLD2 mediated cancer cell migration in human MDA-231 cells at 20 uM by transwell invasion assay2009Nature chemical biology, Feb, Volume: 5, Issue:2
ISSN: 1552-4469		Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID498475Inhibition of PLD1 mediated cancer cell migration in mouse PMT cells at 20 uM by transwell invasion assay2009Nature chemical biology, Feb, Volume: 5, Issue:2
ISSN: 1552-4469		Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID498482Inhibition of human PLD2 assessed as release of methyl-[3H]choline from choline-methyl-[3H]dipalmitoylphosphatidylcholine after 30 mins by exogenous substrate assay2009Nature chemical biology, Feb, Volume: 5, Issue:2
ISSN: 1552-4469		Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID498294Inhibition of PLD1 mediated cancer cell migration in mouse PMT cells at 0.2 uM by transwell invasion assay2009Nature chemical biology, Feb, Volume: 5, Issue:2
ISSN: 1552-4469		Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID515550Selectivity ratio of IC50 for human PLD1 to IC50 for human GST-tagged PLD2A2010Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18
ISSN: 1520-4804		Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitor.
AID498474Inhibition of PLD1 mediated cancer cell migration in mouse 4T1 cells at 20 uM by transwell invasion assay2009Nature chemical biology, Feb, Volume: 5, Issue:2
ISSN: 1552-4469		Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID498293Inhibition of PLD2 mediated cancer cell migration in human MDA-231 cells at 0.2 uM by transwell invasion assay2009Nature chemical biology, Feb, Volume: 5, Issue:2
ISSN: 1552-4469		Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID418767Inhibition of GFP-labelled human PLD2 HEK293 cells2009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
ISSN: 1464-3405		Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity.
AID498284Selectivity ratio of IC50 for human PLD1 to IC50 for human PLD22009Nature chemical biology, Feb, Volume: 5, Issue:2
ISSN: 1552-4469		Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID418768Selectivity for human PLD1 over human PLD22009Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7
ISSN: 1464-3405		Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity.
AID498477Inhibition of PLD1 in human Calu-1 cells assessed as decrease in phosphatidylbutanol-[d9] production after 30 mins by mass spectrometric analysis2009Nature chemical biology, Feb, Volume: 5, Issue:2
ISSN: 1552-4469		Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID498471Inhibition of PLD2 mediated cancer cell migration in mouse PMT cells at 20 uM by transwell invasion assay2009Nature chemical biology, Feb, Volume: 5, Issue:2
ISSN: 1552-4469		Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID1799395PLD1 In Vitro Enzymatic Assay from Article 10.1038/nchembio.140: \\Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.\\2009Nature chemical biology, Feb, Volume: 5, Issue:2
ISSN: 1552-4469		Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID1799396d.311 Enzymatic Inhibition Assay from Article 10.1038/nchembio.140: \\Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.\\2009Nature chemical biology, Feb, Volume: 5, Issue:2
ISSN: 1552-4469		Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID1799398293-PLD2 Cell-Based Assay from Article 10.1038/nchembio.140: \\Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.\\2009Nature chemical biology, Feb, Volume: 5, Issue:2
ISSN: 1552-4469		Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID1799399PLD2 In Vitro Enzymatic Assay from Article 10.1038/nchembio.140: \\Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.\\2009Nature chemical biology, Feb, Volume: 5, Issue:2
ISSN: 1552-4469		Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID1799397Calu-1 Cell-Based Assay from Article 10.1038/nchembio.140: \\Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.\\2009Nature chemical biology, Feb, Volume: 5, Issue:2
ISSN: 1552-4469		Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID1345285Human PLD2 (Hydrolases)2009Nature chemical biology, Feb, Volume: 5, Issue:2
ISSN: 1552-4469		Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
AID1345246Human PLD1 (Phosphatidylcholine-specific phospholipase D)2009Nature chemical biology, Feb, Volume: 5, Issue:2
ISSN: 1552-4469		Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's2 (33.33)24.3611
2020's2 (33.33)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
raloxifene
1
1-benzothiophenes;
aromatic ketone;
N-oxyethylpiperidine;
phenols		bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator		2009200915.0medium000100
4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol
1
stilbenoid2009200915.0medium000100
halopemide
2
2009200915.0high000200
resveratrol
1
resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger		2009200915.0medium000100
diethylstilbestrol
1
olefinic compound;
polyphenol		antifungal agent;
antineoplastic agent;
autophagy inducer;
calcium channel blocker;
carcinogenic agent;
EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
endocrine disruptor;
xenoestrogen		2009200915.0medium000100
tamoxifen
1
stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator		2009200915.0medium000100
5-fluoro-2-indolyldeschlorohalopemide
1
benzimidazoles2009200915.0high000100
N-[2-[4-(2-oxo-3H-benzimidazol-1-yl)-1-piperidinyl]ethyl]-2-naphthalenecarboxamide
2
naphthalenecarboxamide2009200915.0high000200
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Breast Cancer0
1
2009200915.0medium000100
Breast Neoplasms0
1
2009200915.0medium000100
Congenital Zika Syndrome0
1
202020204.0medium000010
Disease Models, Animal0
1
202020204.0medium000010
Invasiveness, Neoplasm0
1
2009200915.0medium000100
Zika Virus Infection0
1
202020204.0medium000010

Bioavailability (1)

ArticleYear
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, , Volume: 96, Issue:5		2019